Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of new therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Innovation is our passion. Driven by VISIONaerie™ science, deep clinical insights, and world-class operational excellence, we are committed to addressing the unmet needs of patients and clinicians.
Aerie’s initial research to find a drug that targeted the main cause of elevated intraocular pressure (IOP) in glaucoma led to the design of a novel small-molecule Rho kinase inhibitor (ROCKi), netarsudil, and the assembly of a proprietary library of thousands of related molecules. In the United States, that ROCKi eye drop became the first drug in a new class to be approved for glaucoma in more than 20 years. A second eyedrop, the fixed-dose combination of the ROCKi and a prostaglandin analog (PGA), is also currently available in the United States.
Aerie is expanding globally, with offices and clinical development activities in Europe and Japan, and a state-of-the-art sterile fill manufacturing facility in Athlone, Ireland; pursuing additional product candidates in ophthalmology, including two clinical-stage retina programs and pre-clinical programs in glaucoma neuroenhancement, retina and dry eye; and exploring the development potential of other assets from its library.